Celularity and DefEYE have announced a partnership focused on advancing regenerative therapies within the field of ophthalmology. According to the companies, the collaboration will combine Celularity’s expertise in placental-derived allogeneic cellular therapies with DefEYE’s research and commercialization capabilities in ophthalmic innovation.
The companies said that the partnership aims to develop and distribute regenerative eye care products designed to address conditions that lead to vision loss and ocular degeneration. The initiative will leverage Celularity’s proprietary placental stem cell technology platform to create potential treatments that could support tissue repair and improve patient outcomes.
According to Celularity, the agreement provides DefEYE with exclusive rights to market and distribute specific regenerative eye care products in defined territories. The company claims that this strategic move aligns with its broader plan to expand the application of its cell-based therapies beyond oncology and immunology into specialty care areas such as ophthalmology.
DefEYE, which focuses on innovations that bridge medical research and consumer applications, said that the partnership strengthens its position in the rapidly growing regenerative medicine market. Both companies stated that they expect this collaboration to accelerate clinical development and bring next-generation regenerative eye care solutions to patients globally.
The companies also said that additional details about the partnership, including product timelines and regulatory strategies, will be announced as development progresses.
The post Celularity and DefEYE partner to expand regenerative therapies in eye care appeared first on Longevity.Technology – Latest News, Opinions, Analysis and Research.
